Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Sickle cell cures are coming. African children can’t be left behind

Jayasree K.Iyer, the Foundation's CEO, writes for STAT about developments in the treatment of sickle cell disease. Despite the fact that gene-based treatments for the debilitating blood disorder could soon be regulated, the expected multi-million dollar cost means it will be out of reach for many.

Date

12 July 2023

Direct links

Read the viewpoint

"The treatment of sickle cell disease is on the cusp of a historic breakthrough, with makers of two gene-based treatments for the debilitating blood disorder hoping for regulatory approval this year.

But for those with sickle cell in sub-Saharan Africa, where more than 60% of the 120 million people worldwide live with this disease, there is little cause to celebrate. A potential cure that could save them from severe illness and early death will exist — but its expected multimillion-dollar price tag will be far out of reach.

Sickle cell disease throws the issue of access to health care into particularly stark relief because it is a major cause of early death and disability among some of the world’s most deprived populations, from Africa to Black communities in the U.S.

The vast majority of those affected by the genetic disorder — in which misshapen blood cells cause anemia, organ damage, severe pain, stroke, and early death — have African ancestry. Indeed, according to the World Health Organization, around 1,000 babies are born every day in Africa with two copies of the sickle hemoglobin gene that causes the disorder, and more than half of them will likely die before they reach the age of 5."

Read the full viewpoint on the STAT website.

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Resource Centre

Explore our research reports and publications
Media

How improving access to essential medicines can help reduce inequities

23 June 2023
Event

Joint event with World Economic Forum on the evolving role of generics – Meeting Report

21 June 2023
Media

Access to medical oxygen: Why are we holding our breath?

05 June 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved